A Phase 1 interventional study of Placebo and PF-06882961 in Type 2 Diabetes Mellitus, sponsored by Pfizer. Completed at 1 site in Japan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-03-11.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Diabetes Mellitus, Type 2 by Pfizer — 2 open to participants now, 3 under way, 3 of them phase 3. Diabetes Mellitus, Type 2 · Pfizer.
Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, this one is the 49th largest by enrollment of the 79 interventional ones that give a count, is one of 2 that started in 2020, is one of 47 in phase 1, and was the 71st registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 80 studies in Diabetes Mellitus, Type 2 by Pfizer are open now, in 11 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Brazil, Canada and 8 more countries
Ages 18+
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 50 across the 79 interventional studies, 32 across the 1 observational. Of the 77 that completed or were terminated, 39 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Diabetes Mellitus, Type 2 by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
Add it to your calendar (.ics) → With an account.
Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, randomized, double blind (sponsor open), parallel, placebo controlled, twice daily oral dosing study of PF 06882961 in adult Japanese participants with T2DM inadequately controlled on diet and exercise alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Participants will be titrated up to 2 weeks to reach desired dose level
Drug: PF-06882961
Participants will be titrated up to 4 weeks to reach desired dose level
Drug: PF-06882961
Participants will be titrated up to 6 weeks to reach desired dose level
Drug: PF-06882961
3 matching placebo tablets taken twice a day (BID)
Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment emergent AEs were events between first dose of study drug and approximately 4 weeks after last dose of study drug, that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and all non-serious AEs.
Time frame: Day 1 of dosing up to approximately 4 weeks after last dose (up to maximum of approximately 12 weeks)
Number of Participants With Clinical Laboratory Abnormalities
Leukocytes (10\^9/liter \[L\]) bilirubin (micromol/L), glucose (millimoles \[mmol\]/L), triacylglycerol lipase (microkatals \[microkat\]/L): greater than (\>) 1.5\*upper limit normal (ULN); activated partial thromboplastin time (s): 1.1\*ULN; HDL cholesterol (mmol/L), thyroid stimulating hormone (TSH) (milliunits \[mU\]/L): less than (\<) 0.8\*lower limit normal (LLN); LDL cholesterol (mmol/L), urate (mmol/L): \>1.2\*ULN; triglycerides: \>1.3\*ULN; aspartate aminotransferase (microkat/L), alanine aminotransferase (microkat/L), gamma glutamyl transferase (microkat/L): \>3.0\*ULN; cholesterol (mmol/L): \>1.3\*ULN; urine glucose, ketones urine protein, urine hemoglobin, urobilinogen, nitrite, leukocyte esterase: greater than or equal to (\>=) 1; granular casts, hyaline casts: \>1.
Time frame: Day 1 of dosing up to approximately 4 weeks after last dose (up to maximum of approximately 12 weeks)
Number of Participants With Absolute Vital Signs (SBP, DBP and Pulse Rate) Values; Increased and Decreased Vital Signs (SBP, DBP) Values From Time-Matched Baseline
Supine systolic blood pressure (SBP) measured in millimeter of mercury (mmHg) had following categories: minimum of absolute SBP \<90 mmHg, maximum of SBP \>=30 mmHg decrease from baseline and maximum of SBP \>=30 mmHg increase from baseline. Supine diastolic blood pressure (DBP) measured in mmHg had following categories: minimum of absolute DBP \<50 mmHg, maximum of DBP \>20 mmHg decrease from baseline and maximum of DBP \>=20 mmHg increase from baseline. Supine pulse rate measured in beats per minute (BPM) had following categories: minimum of absolute supine pulse rate \<40 BPM and maximum of absolute supine pulse rate \>120 BPM. Baseline was defined as the time-matched value from the average of the triplicate recordings on Day -1.
Time frame: Baseline (1 Day before dosing) up to last dose (maximum up to Week 8)
Number of Participants With Absolute Electrocardiogram (ECG) Values and Increased ECG Values From Time-Matched Baseline
PR interval had following categories: maximum absolute PR interval \>=300 milliseconds (msec); when baseline PR interval \>200 msec and maximum increase from baseline in PR interval \>=25 percent; when baseline PR interval less than or equal to (\<=) 200 msec and maximum increase from baseline in PR interval \>=50 percent. QRS interval had following categories: maximum absolute QRS interval \>=140 msec; maximum increase from baseline in QRS interval \>=50 percent. QTC interval with Frederica's correction (QTCF) had following categories: absolute QTCF interval \>450 msec to \<=480 msec; absolute QTCF interval \>480 msec to \<=500 msec; absolute QTCF interval \>500 msec; QTCF interval increase from baseline \>=30 msec to \<=60 msec; QTCF interval increase from baseline \>60 msec.
Time frame: Baseline (1 Day before dosing) up to last dose (maximum up to Week 8)
Area Under the Plasma Concentration-time Profile From Zero to Time 24 Hours (AUC24) of PF-06882961
AUC24= Area under the plasma concentration versus time curve from time zero (pre-dose) to time 24 hours (0-24).
Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours post dose on Day 1 and 56
Maximum Plasma Concentration (Cmax) Observed of PF-06882961
Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours post dose on Day 1; Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14, 24, 36 and 48 hours on Day 56
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06882961
Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours post dose on Day 1; Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14, 24, 36 and 48 hours on Day 56
Terminal Phase Half-Life (t1/2) of PF-06882961
t1/2 was calculated as loge (2) per kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 10, 12, 14, 24, 36 and 48 hours on Day 56
| Milestone | Placebo | PF-06882961 40 mg | PF-06882961 80 mg | PF-06882961 120 mg |
|---|---|---|---|---|
| Started | 9 | 10 | 9 | 9 |
| Completed | 9 | 10 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment emergent AEs were events between first dose of study drug and approximately 4 weeks after last dose of study drug, that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and all non-serious AEs.
| Participants | Placebo | PF-06882961 40 mg | PF-06882961 80 mg | PF-06882961 120 mg |
|---|---|---|---|---|
| Participants with AEs | 3 | 7 | 9 | 9 |
| Participants with SAEs | 0 | 0 | 0 | 0 |
Leukocytes (10\^9/liter \[L\]) bilirubin (micromol/L), glucose (millimoles \[mmol\]/L), triacylglycerol lipase (microkatals \[microkat\]/L): greater than (\>) 1.5\*upper limit normal (ULN); activated partial thromboplastin time (s): 1.1\*ULN; HDL cholesterol (mmol/L), thyroid stimulating hormone (TSH) (milliunits \[mU\]/L): less than (\<) 0.8\*lower limit normal (LLN); LDL cholesterol (mmol/L), urate (mmol/L): \>1.2\*ULN; triglycerides: \>1.3\*ULN; aspartate aminotransferase (microkat/L), alanine aminotransferase (microkat/L), gamma glutamyl transferase (microkat/L): \>3.0\*ULN; cholesterol (mmol/L): \>1.3\*ULN; urine glucose, ketones urine protein, urine hemoglobin, urobilinogen, nitrite, leukocyte esterase: greater than or equal to (\>=) 1; granular casts, hyaline casts: \>1.
| Participants | Placebo | PF-06882961 40 mg | PF-06882961 80 mg | PF-06882961 120 mg |
|---|---|---|---|---|
| Number of Participants With Clinical Laboratory Abnormalities | 9 | 10 | 8 | 9 |
Supine systolic blood pressure (SBP) measured in millimeter of mercury (mmHg) had following categories: minimum of absolute SBP \<90 mmHg, maximum of SBP \>=30 mmHg decrease from baseline and maximum of SBP \>=30 mmHg increase from baseline. Supine diastolic blood pressure (DBP) measured in mmHg had following categories: minimum of absolute DBP \<50 mmHg, maximum of DBP \>20 mmHg decrease from baseline and maximum of DBP \>=20 mmHg increase from baseline. Supine pulse rate measured in beats per minute (BPM) had following categories: minimum of absolute supine pulse rate \<40 BPM and maximum of absolute supine pulse rate \>120 BPM. Baseline was defined as the time-matched value from the average of the triplicate recordings on Day -1.
| Participants | Placebo | PF-06882961 40 mg | PF-06882961 80 mg | PF-06882961 120 mg |
|---|---|---|---|---|
| Minimum of absolute SBP <90 mmHg | 0 | 0 | 0 | 0 |
| Maximum of SBP >=30 mmHg decrease | 1 | 0 | 0 | 1 |
| Maximum of SBP >=30 mmHg increase | 3 | 2 | 3 | 2 |
| Minimum of absolute DBP <50 mmHg | 0 | 0 | 0 | 0 |
| Maximum of DBP >=20 mmHg decrease | 0 | 0 | 0 | 0 |
| Maximum of DBP >=20 mmHg increase | 1 | 2 | 3 | 3 |
| Minimum of absolute pulse rate <40 BPM | 0 | 0 | 0 | 0 |
| Maximum of absolute pulse rate >120 BPM | 0 | 0 | 0 | 0 |
PR interval had following categories: maximum absolute PR interval \>=300 milliseconds (msec); when baseline PR interval \>200 msec and maximum increase from baseline in PR interval \>=25 percent; when baseline PR interval less than or equal to (\<=) 200 msec and maximum increase from baseline in PR interval \>=50 percent. QRS interval had following categories: maximum absolute QRS interval \>=140 msec; maximum increase from baseline in QRS interval \>=50 percent. QTC interval with Frederica's correction (QTCF) had following categories: absolute QTCF interval \>450 msec to \<=480 msec; absolute QTCF interval \>480 msec to \<=500 msec; absolute QTCF interval \>500 msec; QTCF interval increase from baseline \>=30 msec to \<=60 msec; QTCF interval increase from baseline \>60 msec.
| Participants | Placebo | PF-06882961 40 mg | PF-06882961 80 mg | PF-06882961 120 mg |
|---|---|---|---|---|
| Maximum absolute PR >=300 msec | 0 | 0 | 0 | 0 |
| Baseline PR >200 msec and maximum increase in PR >=25% | 0 | 0 | 0 | 0 |
| Baseline PR <=200 msec and maximum increase in PR >=50% | 0 | 0 | 0 | 0 |
| Maximum absolute QRS >=140 msec | 0 | 0 | 0 | 0 |
| Maximum increase in QRS >=50% | 0 | 0 | 0 | 0 |
| Absolute QTCF interval >450 msec to <=480 msec | 1 | 0 | 1 | 1 |
| Absolute QTCF interval >480 msec to <=500 msec | 0 | 0 | 0 | 0 |
| Absolute QTCF >500 msec | 0 | 0 | 0 | 0 |
| QTCF increase >=30 msec to <=60 msec | 0 | 0 | 0 | 0 |
| QTCF increase >60 msec | 0 | 0 | 0 | 0 |
AUC24= Area under the plasma concentration versus time curve from time zero (pre-dose) to time 24 hours (0-24).
| Nanogram*hour per milliliter | PF-06882961 40 mg | PF-06882961 80 mg | PF-06882961 120 mg |
|---|---|---|---|
| Day 1 | 414.4 ± 58 | 500.3 ± 58 | 484.5 ± 73 |
| Day 56 | 2424 ± 45 | 4691 ± 75 | 6953 ± 148 |
| Nanogram per milliliter | PF-06882961 40 mg | PF-06882961 80 mg | PF-06882961 120 mg |
|---|---|---|---|
| Day 1 | 32.83 ± 55 | 45.89 ± 52 | 39.35 ± 80 |
| Day 56 | 206.1 ± 54 | 352.2 ± 75 | 551.7 ± 153 |
| Hours | PF-06882961 40 mg | PF-06882961 80 mg | PF-06882961 120 mg |
|---|---|---|---|
| Day 1 | 12.0 (2.00 to 23.8) | 12.0 (1.00 to 12.0) | 12.0 (1.00 to 14.0) |
| Day 56 | 12.0 (6.00 to 13.8) | 12.9 (2.00 to 36.0) | 12.0 (0.000 to 13.8) |
t1/2 was calculated as loge (2) per kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| Hours | PF-06882961 40 mg | PF-06882961 80 mg | PF-06882961 120 mg |
|---|---|---|---|
| Terminal Phase Half-Life (t1/2) of PF-06882961 | 6.373 ± 1.7404 | 5.543 ± 0.30827 | 5.300 ± 0.80594 |
Collected over Day 1 of dosing up to approximately 4 weeks after last dose (up to maximum of approximately 12 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/9 (0%) | 0/9 (0%) | 3/9 (33.3%) |
| PF-06882961 40 mg | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| PF-06882961 80 mg | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| PF-06882961 120 mg | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| Event | Placebo | PF-06882961 40 mg | PF-06882961 80 mg | PF-06882961 120 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/9 | 6/10 | 8/9 | 4/9 |
| VomitingGastrointestinal disorders | 0/9 | 5/10 | 6/9 | 5/9 |
| Abdominal discomfortGastrointestinal disorders | 0/9 | 4/10 | 4/9 | 5/9 |
| DiarrhoeaGastrointestinal disorders | 0/9 | 1/10 | 2/9 | 1/9 |
| HeadacheNervous system disorders | 1/9 | 2/10 | 1/9 | 0/9 |
| Abdominal pain upperGastrointestinal disorders | 0/9 | 0/10 | 1/9 | 0/9 |
| Dental cariesGastrointestinal disorders | 1/9 | 0/10 | 0/9 | 1/9 |
| StomatitisGastrointestinal disorders | 0/9 | 0/10 | 1/9 | 0/9 |
| InfluenzaInfections and infestations | 0/9 | 0/10 | 0/9 | 1/9 |
| Lipase increasedInvestigations | 1/9 | 0/10 | 0/9 | 0/9 |
Safety analysis set included all participants who were randomly assigned to study intervention and who took at least 1 dose of study intervention.
| Age, Continuous(Years) | Placebo | PF-06882961 40 mg | PF-06882961 80 mg | PF-06882961 120 mg | Total |
|---|---|---|---|---|---|
| Mean | 58.6 ± 8.75 | 55.9 ± 10.04 | 58.0 ± 6.69 | 50.7 ± 7.50 | 55.8 ± 8.62 |
| Sex: Female, Male(Participants) | Placebo | PF-06882961 40 mg | PF-06882961 80 mg | PF-06882961 120 mg | Total |
|---|---|---|---|---|---|
| Female | 1 | 2 | 1 | 1 | 5 |
| Male | 8 | 8 | 8 | 8 | 32 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | PF-06882961 40 mg | PF-06882961 80 mg | PF-06882961 120 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 9 | 10 | 9 | 9 | 37 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | PF-06882961 40 mg | PF-06882961 80 mg | PF-06882961 120 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 9 | 10 | 9 | 9 | 37 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Oct 2020 to primary completion in Mar 2021, 4 months.
Results were first posted in Mar 2022, 11 months after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 4 months is below that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Danuglipron